Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) is frequently in the news as a global company focused on pet healthcare innovation, veterinary diagnostics, and software. News about IDEXX often highlights product launches, diagnostic advances, financial results, and corporate governance updates, reflecting its role in companion animal care, livestock and dairy health, and water safety.
Recent announcements include new diagnostic imaging and cancer testing capabilities. IDEXX has introduced the Vue DR50 Plus Digital Imaging System, described as its most advanced diagnostic imaging solution for veterinary practices, combining high-definition, AI-powered imaging with lower radiation doses compared with earlier IDEXX systems and other veterinary imaging solutions. The company has also reported expansions of its IDEXX Cancer Dx Panel and applications on the inVue Dx Cellular Analyzer, aimed at providing earlier insights and rapid, in-clinic answers for canine cancer cases.
Investors and veterinary professionals following IDXX news will also encounter quarterly earnings releases, where IDEXX discusses revenue growth, earnings per share, and performance across areas such as the Companion Animal Group, Water, and Livestock, Poultry and Dairy. Additional news items cover topics like CEO succession planning, board appointments, and participation in investor conferences.
This news page aggregates these types of updates so readers can review IDEXX’s latest disclosures on diagnostics, software, AI-enabled tools, telemedicine services, and financial performance. For anyone tracking IDXX stock, veterinary sector developments, or advances in animal health diagnostics, this feed provides a centralized view of the company’s publicly reported developments over time.
IDEXX Laboratories (NASDAQ: IDXX) has announced a time change for its 2024 second quarter financial results conference call. The call will now take place at 9:00 am ET on Tuesday, August 6, 2024. This adjustment aims to minimize conflicts with other industry earnings announcements. Investors can access the live webcast, transcript, and Q2 2024 Earnings Snapshot through the company's website at www.idexx.com/investors. An archived version of the webcast will be available after 1:00 pm ET on the same day and will remain accessible for one year. For those preferring to listen via telephone, the call can be accessed by dialing 1-800-289-0459 or 1-773-305-6837 with passcode 399723.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has released its 2023 Corporate Responsibility Report, highlighting progress in pet healthcare innovation and corporate responsibility goals. Key achievements include:
Healthcare Advancements: Launch of IDEXX Cystatin B Test for kidney injury detection and development of new products like IDEXX inVue Dx™ Cellular Analyzer.
Community Support: Enabled access to care for over 245,000 animals in underserved communities in 2023.
Workplace Initiatives: Maintained gender balance in global management roles, supported women in STEM, and logged over 73,000 hours of employee learning and development.
Environmental Progress: Procured a virtual power purchase agreement for clean electricity in North America and installed a dual-source energy system at a European reference laboratory.
IDEXX Laboratories (NASDAQ: IDXX) will release its 2024 second quarter financial results on August 6, 2024, before market opening. An analyst conference call will follow at 8:30 a.m. EDT, accessible via webcast and telephone. The webcast and a transcript will be available on IDEXX's investor website and archived for a year. In addition, IDEXX will hold its 2024 Investor Day on August 15, 2024, at its headquarters in Westbrook, Maine, from 8:00 a.m. to noon EDT. Institutional investors and analysts can attend in person with prior registration or follow the live webcast.
IDEXX Laboratories has launched the Catalyst Pancreatic Lipase Test, designed for rapid detection of pancreatitis in cats and dogs.
The test provides quantitative results in under 10 minutes and will be available in the U.S. and Canada by September, followed by a global rollout in Q4 2024.
The test is part of IDEXX's Catalyst platform, which aims to enhance diagnostic capabilities for veterinarians worldwide. The Catalyst SmartQC Control, a new quality control system that is 90% faster than current methods, will also be launched in Q4 2024.
Both innovations aim to streamline diagnostic workflows and improve patient outcomes.
IDEXX Laboratories (NASDAQ: IDXX) announced that Brian McKeon, EVP & CFO, and Michael Lane, EVP & GM of Reference Laboratories and IT, will participate in a fireside chat at the Stifel Jaws & Paws Conference on May 29, 2024, from 10:55 am to 11:25 am (EDT). A live audio webcast will be available on IDEXX's website, with an archived edition accessible later.
The company also announced its 2024 Investor Day on August 15, 2024, at its headquarters in Westbrook, Maine, from 8:00 am to 12:00 pm (EDT). The event will be webcast live, with advance registration required for in-person attendance by institutional investors and analysts.
IDEXX Laboratories, a global leader in pet healthcare innovation, announced first quarter results with revenue growth of 7% supported by CAG Diagnostics recurring revenue growth of 7%. The company achieved EPS of $2.81 and updated its 2024 revenue guidance to $3,895 million - $3,965 million, and EPS outlook to $10.82 - $11.20.
Summary not available.
Summary not available.
Summary not available.
Summary not available.